Overview: OncoPro Endometrial Cancer Prognostic TestIntroduction: The OncoPro Endometrial Cancer Prognostic Test screens microsatellite instability (MSI) and NGS for endometrial cancer prognosis, aiding treatment planning. Following 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding prognosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected endometrial cancer.
Other Names: Endometrial Cancer Panel, MSI/NGS Prognostic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Endometrial cancer prognostic testing began in the 2000s with MSI and POLE discoveries. NGS methods improved in the 2010s, enhancing prognostic precision.
Purpose: Screens MSI and NGS for endometrial cancer prognosis, guides treatment, and evaluates patients with endometrial cancer.
Test Parameters: 1. MSI and Endometrial Cancer Genes
Pretest Condition: No fasting required. Collect tissue. Report history of abnormal uterine bleeding or endometrial cancer symptoms.
Specimen: Tissue (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document abnormal uterine bleeding, pelvic pain, or family history of endometrial cancer. Include current medications, especially hormonal therapies.
Consent: Written consent required, detailing the tests purpose, endometrial cancer implications, and risks of tissue collection.
Procedural Considerations: Uses next-generation sequencing and MSI analysis to assess endometrial cancer genes (e.g., POLE, PTEN). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for endometrial cancer prognosis.
Factors Affecting Result Accuracy: Low DNA yield or improper tissue storage can affect results. Contamination may reduce specificity.
Clinical Significance: MSI-high or specific mutations guide immunotherapy or surgical planning. Negative results may require additional molecular testing.
Specialist Consultation: Consult an oncologist or gynecologist for result interpretation and treatment planning.
Additional Supporting Tests: Endometrial biopsy, pelvic ultrasound, or tumor markers to confirm endometrial cancer diagnosis.
Test Limitations: Not all endometrial cancers have MSI or detectable mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Endometrial Cancer Guidelines, 2023; Journal of Clinical Oncology, Levine DA, 2022.
